Video yükleniyor...

Video Yüklenemedi

Bu video yüklenirken bir sorun oluştu. Bu geçici bir ağ sorunundan kaynaklanıyor olabilir veya video kullanılamıyor olabilir.

Ana Sayfaya Dön

𝐅𝐫𝐨𝐦 𝐭𝐡𝐞 𝐁𝐚𝐲 𝐀𝐫𝐞𝐚: Gordian Biotechnology announced that it will be using its unique large-scale in vivo screening process to help Pfizer look for new targets against obesity. Co Founder & CSO Martin Borch Jensen explains how it works. Full video:

BiotechTV

11,475 subscribers

13,213 görüntüleme • 7 ay önce •via X (Twitter)

Anya Rossi• Live Now

Private livecam show

0 Yorum

Yorum bulunmuyor

Orijinal gönderinin yorumları burada görünecek

Benzer Videolar

𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: ArsenalBio Co-Founder & CEO ken drazan talks about engineering the next generation of T-cell therapies, including a clinical stage renal cell program that includes multiple features. Full video:

𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: ArsenalBio Co-Founder & CEO ken drazan talks about engineering the next generation of T-cell therapies, including a clinical stage renal cell program that includes multiple features. Full video:

BiotechTV

11,057 görüntüleme • 1 yıl önce

𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: AstraZeneca's CEO Pascal Soriot shares his take on M&A, oncology, Baxfendy for hypertension, the obesity market, and more. $AZN Full video:

𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: AstraZeneca's CEO Pascal Soriot shares his take on M&A, oncology, Baxfendy for hypertension, the obesity market, and more. $AZN Full video:

BiotechTV

36,428 görüntüleme • 4 ay önce

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: After switching to a new GalNAc-LNP delivery vehicle a year ago, @VerveTx today announced the initial safety and efficacy data from its VERVE-102 PCSK9 based editor. Co-Founder & CEO Sek Kathiresan MD covers the data. $VERV Full video:

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: After switching to a new GalNAc-LNP delivery vehicle a year ago, @VerveTx today announced the initial safety and efficacy data from its VERVE-102 PCSK9 based editor. Co-Founder & CEO Sek Kathiresan MD covers the data. $VERV Full video:

BiotechTV

22,484 görüntüleme • 1 yıl önce

𝐀𝐒𝐇 𝟐𝟎𝟐𝟓: KeloniaTx presented convincing late-breaking data at ASH today from its initial patients in multiple myeloma suggesting that in vivo CAR-T is on track to be a next innovation. Full video:

𝐀𝐒𝐇 𝟐𝟎𝟐𝟓: KeloniaTx presented convincing late-breaking data at ASH today from its initial patients in multiple myeloma suggesting that in vivo CAR-T is on track to be a next innovation. Full video:

BiotechTV

21,987 görüntüleme • 10 ay önce

𝐅𝐫𝐨𝐦 𝐋𝐮𝐧𝐝: Asgard Therapeutics aims to turn tumor cells into a type of dendritic cell inside the body with that the immune system can learn the tumor's signature and fight it systemically. Full video:

𝐅𝐫𝐨𝐦 𝐋𝐮𝐧𝐝: Asgard Therapeutics aims to turn tumor cells into a type of dendritic cell inside the body with that the immune system can learn the tumor's signature and fight it systemically. Full video:

BiotechTV

10,370 görüntüleme • 4 ay önce

𝐅𝐫𝐨𝐦 𝐒𝐞𝐨𝐮𝐥: Daejeon based Orum Therapeutics is pioneering the field of degrader-antibody conjugates. Founder SJ Lee describes the science and gives us an overview of biotech in Korea. Full video:

𝐅𝐫𝐨𝐦 𝐒𝐞𝐨𝐮𝐥: Daejeon based Orum Therapeutics is pioneering the field of degrader-antibody conjugates. Founder SJ Lee describes the science and gives us an overview of biotech in Korea. Full video:

BiotechTV

15,588 görüntüleme • 1 yıl önce

Gordian Biotechnology Martin Borch Jensen argues AI drug discovery will crack cancer before Alzheimer's for the same reason it cracks math and code but not financial markets: verifiability "Biotech is the business of building confidence around whether X is the right way to do something. What works really well is when you get a super clear signal about whether the thing worked." "For weight loss, you can order your peptides from China, and two weeks later, if they work, you lost a bunch of weight. If you can get a scan and see your tumor is gone, that will work really well." "For preventing you from having a heart attack or slowing down Alzheimer's, that's gonna be much, much harder." "It's really just verifiability. We do really well at math because you can do formal verification of whether this theorem is true. We do really well at code because you can run the code and see whether it works." "We have yet to make a lot of money on financial markets or invent new forms of government or all this fuzzy, annoying stuff. Same principle applied to bio." Gordian Biotechnology

Gordian Biotechnology Martin Borch Jensen argues AI drug discovery will crack cancer before Alzheimer's for the same reason it cracks math and code but not financial markets: verifiability "Biotech is the business of building confidence around whether X is the right way to do something. What works really well is when you get a super clear signal about whether the thing worked." "For weight loss, you can order your peptides from China, and two weeks later, if they work, you lost a bunch of weight. If you can get a scan and see your tumor is gone, that will work really well." "For preventing you from having a heart attack or slowing down Alzheimer's, that's gonna be much, much harder." "It's really just verifiability. We do really well at math because you can do formal verification of whether this theorem is true. We do really well at code because you can run the code and see whether it works." "We have yet to make a lot of money on financial markets or invent new forms of government or all this fuzzy, annoying stuff. Same principle applied to bio." Gordian Biotechnology

MTS

12,591 görüntüleme • 1 ay önce

𝐄𝐩𝐢𝐠𝐞𝐧𝐞𝐭𝐢𝐜𝐬: BiotechTV visited NewLimit in South San Francisco and heard from Co-Founder & President Jacob Kimmel how they are trying to tackle diseases of aging through epigenetic reprogramming.

𝐄𝐩𝐢𝐠𝐞𝐧𝐞𝐭𝐢𝐜𝐬: BiotechTV visited NewLimit in South San Francisco and heard from Co-Founder & President Jacob Kimmel how they are trying to tackle diseases of aging through epigenetic reprogramming.

BiotechTV

85,263 görüntüleme • 7 ay önce

𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟔: Bicara Therapeutics is presenting long-term follow up data at ASCO that it believes shows durability derived from choosing TGF-β with EGFR for its fusion protein in HPV negative head & neck. $BCAX #ASCO26 Full video:

𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟔: Bicara Therapeutics is presenting long-term follow up data at ASCO that it believes shows durability derived from choosing TGF-β with EGFR for its fusion protein in HPV negative head & neck. $BCAX #ASCO26 Full video:

BiotechTV

11,745 görüntüleme • 4 ay önce

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Abivax CEO Marc de Garidel discusses freshly released maintenance part 2 results for obefazimod in UC and describes how he believes it builds on initial data announced earlier this month. $ABVX Watch the full video:

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Abivax CEO Marc de Garidel discusses freshly released maintenance part 2 results for obefazimod in UC and describes how he believes it builds on initial data announced earlier this month. $ABVX Watch the full video:

BiotechTV

22,305 görüntüleme • 3 ay önce

Anthropic co-founder Chris Olah: There is a real possibility that AI will displace human labor at a very large scale. If that happens, supporting those displaced will be a moral imperative of historic proportions. AI development is concentrated in a handful of wealthy nations. How will we ensure that the gains of AI are shared globally? We do not have a mechanism for this. It is an unsolved problem.

Anthropic co-founder Chris Olah: There is a real possibility that AI will displace human labor at a very large scale. If that happens, supporting those displaced will be a moral imperative of historic proportions. AI development is concentrated in a handful of wealthy nations. How will we ensure that the gains of AI are shared globally? We do not have a mechanism for this. It is an unsolved problem.

Clash Report

80,787 görüntüleme • 4 ay önce

Peskov has outdone himself in cynicism “You know that at the moment the peace process is on pause. We expect that it will eventually be resumed. As for the strikes by our armed forces, they are carried out only against military or quasi-military targets. In this regard, it is also worth once again paying attention to the ongoing strikes by the armed forces of Ukraine using drones against civilian targets and civilian infrastructure in various Russian cities and settlements,” he said.

Peskov has outdone himself in cynicism “You know that at the moment the peace process is on pause. We expect that it will eventually be resumed. As for the strikes by our armed forces, they are carried out only against military or quasi-military targets. In this regard, it is also worth once again paying attention to the ongoing strikes by the armed forces of Ukraine using drones against civilian targets and civilian infrastructure in various Russian cities and settlements,” he said.

NEXTA

54,659 görüntüleme • 4 ay önce

𝐁𝐫𝐞𝐚𝐤𝐢𝐧𝐠 𝐌&𝐀 𝐍𝐞𝐰𝐬: Lilly is acquiring Crossbridgebio, a Texas biotech developing dual payload antibody-drug conjugates, for up to $300M. Co-Founder & CEO Michael Torres tells us.

𝐁𝐫𝐞𝐚𝐤𝐢𝐧𝐠 𝐌&𝐀 𝐍𝐞𝐰𝐬: Lilly is acquiring Crossbridgebio, a Texas biotech developing dual payload antibody-drug conjugates, for up to $300M. Co-Founder & CEO Michael Torres tells us.

BiotechTV

20,285 görüntüleme • 6 ay önce

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Aerska launched in the UK today with $21M in financing to develop RNAi medicines for neurological conditions that are delivered to the brain via 'brain shuttle' technologies. CEO Jack O'Meara explains. Full video:

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Aerska launched in the UK today with $21M in financing to develop RNAi medicines for neurological conditions that are delivered to the brain via 'brain shuttle' technologies. CEO Jack O'Meara explains. Full video:

BiotechTV

19,198 görüntüleme • 1 yıl önce

You already own stocks. So why tokenize them? Chainlink Co-founder Sergey Nazarov says they're more than simply owning a stock onchain. The value, he explains, is better yield, assets that move around the clock, and lower funding costs, which add up to billions in savings for large banks. The catch: it only works once enough market participants are on the same system. FULL INTERVIEW BELOW.

You already own stocks. So why tokenize them? Chainlink Co-founder Sergey Nazarov says they're more than simply owning a stock onchain. The value, he explains, is better yield, assets that move around the clock, and lower funding costs, which add up to billions in savings for large banks. The catch: it only works once enough market participants are on the same system. FULL INTERVIEW BELOW.

The Rollup

12,319 görüntüleme • 10 gün önce